(Q47582593)

4 February 2018

title

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality (English)

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00627-8

18 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00627-8

18 March 2024

author name string

Nelson Stone

series ordinal

3

1 reference

4 February 2018

Marisa A. Kollmeier

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529768

18 March 2024

Richard G. Stock

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529768

18 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

4 February 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0360301603006278?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00627-8

https://api.elsevier.com/content/article/PII:S0360301603006278?httpAccept=text/plain

18 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00627-8

International Journal of Radiation Oncology Biology Physics

18 March 2024

published in

1 reference

4 February 2018

volume

57

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

645-653

1 reference

4 February 2018

Iodine-125 brachytherapy for clinically localized prostate cancer: a 5-year follow-up of outcome and complications

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

A dose-response study for I-125 prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Prostate-specific antigen spikes after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Biochemical disease-free survival following 125I prostate implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900627-8

7 January 2021

Identifiers

1 reference

4 February 2018

1 reference

4 February 2018